PE20220500A1 - POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 - Google Patents
POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15Info
- Publication number
- PE20220500A1 PE20220500A1 PE2021001749A PE2021001749A PE20220500A1 PE 20220500 A1 PE20220500 A1 PE 20220500A1 PE 2021001749 A PE2021001749 A PE 2021001749A PE 2021001749 A PE2021001749 A PE 2021001749A PE 20220500 A1 PE20220500 A1 PE 20220500A1
- Authority
- PE
- Peru
- Prior art keywords
- region
- gdf15
- immunoglobulin
- fusion polypeptide
- functional variant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Polipeptido de fusion, que comprende GDF15 (factor de crecimiento/diferenciacion 15) o su variante funcional, y region Fc de una inmunoglobulina, en el que, la region Fc de la inmunoglobulina es una cadena simple de region Fc de IgG1 o region Fc de IgG4, y esta unida al extremo N-terminal del GDF15 o su variante funcional, a traves de un ligador peptidico flexible, la variante funcional de GDF15 es una variante de delecion en la que al menos uno de los 14 aminoacidos en las posiciones 1 a 14 de la secuencia de aminoacidos de SEQ ID NO: 1 estan delecionados, y el ligador peptidico flexible esta representado por (GGGGS)n (n es 1, 2, 3, 4 o 5). Una composicion farmaceutica que comprende el polipeptido de fusion y un metodo de aumentar la duracion in vivo de GDF15 que comprende fusionar con una region Fc de inmunoglobulina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190047558 | 2019-04-23 | ||
| PCT/KR2020/005324 WO2020218827A1 (ko) | 2019-04-23 | 2020-04-22 | 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220500A1 true PE20220500A1 (es) | 2022-04-07 |
Family
ID=72941168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001749A PE20220500A1 (es) | 2019-04-23 | 2020-04-22 | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230053119A1 (es) |
| EP (1) | EP3978518A4 (es) |
| JP (2) | JP2022530216A (es) |
| KR (2) | KR20200124176A (es) |
| CN (1) | CN113767112A (es) |
| AU (1) | AU2020260931B2 (es) |
| BR (1) | BR112021021271A2 (es) |
| CA (1) | CA3136969A1 (es) |
| CL (1) | CL2021002757A1 (es) |
| CO (1) | CO2021014413A2 (es) |
| IL (1) | IL287343A (es) |
| JO (1) | JOP20210282A1 (es) |
| MX (1) | MX2021012964A (es) |
| MY (1) | MY208040A (es) |
| PE (1) | PE20220500A1 (es) |
| PH (1) | PH12021552662A1 (es) |
| SG (1) | SG11202111570TA (es) |
| TW (2) | TWI892985B (es) |
| UA (1) | UA128626C2 (es) |
| WO (1) | WO2020218827A1 (es) |
| ZA (1) | ZA202108437B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036985B1 (ru) | 2014-10-31 | 2021-01-25 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Композиции и способы лечения метаболических расстройств |
| WO2022245183A1 (en) * | 2021-05-21 | 2022-11-24 | Yuhan Corporation | Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant |
| US20240350588A1 (en) * | 2021-08-24 | 2024-10-24 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and use thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE240395T1 (de) * | 1994-03-29 | 2003-05-15 | Celltech Therapeutics Ltd | Antikörper gegen e-selektin |
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| MXPA05013565A (es) * | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| RU2352583C2 (ru) | 2003-11-13 | 2009-04-20 | Ханми Фарм. Инд. Ко., Лтд. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ |
| KR101868139B1 (ko) | 2010-11-30 | 2018-06-15 | 주식회사 엘지화학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
| KR101038126B1 (ko) | 2010-11-30 | 2011-05-31 | 주식회사 엘지생명과학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
| ES2676499T3 (es) * | 2011-04-13 | 2018-07-20 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| CN104204218A (zh) * | 2012-01-26 | 2014-12-10 | 安姆根有限公司 | 生长分化因子15 (gdf-15)多肽 |
| WO2013148117A1 (en) * | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| TWI513705B (zh) * | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| RU2704285C2 (ru) * | 2013-01-30 | 2019-10-25 | Нгм Байофармасьютикалз, Инк. | Композиции и способы применения для лечения метаболических расстройств |
| BR112016002213A2 (pt) * | 2013-07-31 | 2017-08-29 | Amgen Inc | Construtos do fator 15 de diferenciação de crescimento (gdf-15) |
| KR102092225B1 (ko) | 2014-04-30 | 2020-03-23 | 주식회사 엘지화학 | 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터 |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EA036985B1 (ru) * | 2014-10-31 | 2021-01-25 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Композиции и способы лечения метаболических расстройств |
| SMT202300026T1 (it) * | 2015-05-18 | 2023-03-17 | Pieris Pharmaceuticals Gmbh | Polipeptide di fusione anti-cancro |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2017109706A1 (en) * | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| CN108424460A (zh) * | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
| PE20201350A1 (es) * | 2018-04-09 | 2020-11-30 | Amgen Inc | Proteinas de fusion del factor de diferenciacion de crecimiento 15 |
-
2020
- 2020-04-22 CA CA3136969A patent/CA3136969A1/en active Pending
- 2020-04-22 UA UAA202105934A patent/UA128626C2/uk unknown
- 2020-04-22 MY MYPI2021006280A patent/MY208040A/en unknown
- 2020-04-22 AU AU2020260931A patent/AU2020260931B2/en active Active
- 2020-04-22 EP EP20793990.1A patent/EP3978518A4/en active Pending
- 2020-04-22 SG SG11202111570TA patent/SG11202111570TA/en unknown
- 2020-04-22 MX MX2021012964A patent/MX2021012964A/es unknown
- 2020-04-22 TW TW109113479A patent/TWI892985B/zh active
- 2020-04-22 WO PCT/KR2020/005324 patent/WO2020218827A1/ko not_active Ceased
- 2020-04-22 PH PH1/2021/552662A patent/PH12021552662A1/en unknown
- 2020-04-22 TW TW112122841A patent/TW202337914A/zh unknown
- 2020-04-22 JP JP2021562863A patent/JP2022530216A/ja active Pending
- 2020-04-22 KR KR1020200048925A patent/KR20200124176A/ko not_active Ceased
- 2020-04-22 JO JOP/2021/0282A patent/JOP20210282A1/ar unknown
- 2020-04-22 US US17/605,798 patent/US20230053119A1/en active Pending
- 2020-04-22 BR BR112021021271A patent/BR112021021271A2/pt unknown
- 2020-04-22 CN CN202080030773.8A patent/CN113767112A/zh active Pending
- 2020-04-22 PE PE2021001749A patent/PE20220500A1/es unknown
-
2021
- 2021-06-24 KR KR1020210082625A patent/KR102609627B1/ko active Active
- 2021-10-18 IL IL287343A patent/IL287343A/en unknown
- 2021-10-20 CL CL2021002757A patent/CL2021002757A1/es unknown
- 2021-10-27 CO CONC2021/0014413A patent/CO2021014413A2/es unknown
- 2021-10-29 ZA ZA2021/08437A patent/ZA202108437B/en unknown
-
2023
- 2023-06-20 JP JP2023101082A patent/JP2023115118A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL287343A (en) | 2021-12-01 |
| CO2021014413A2 (es) | 2021-11-19 |
| ZA202108437B (en) | 2023-07-26 |
| AU2020260931B2 (en) | 2023-08-24 |
| CN113767112A (zh) | 2021-12-07 |
| JP2023115118A (ja) | 2023-08-18 |
| WO2020218827A1 (ko) | 2020-10-29 |
| KR102609627B1 (ko) | 2023-12-04 |
| SG11202111570TA (en) | 2021-11-29 |
| BR112021021271A2 (pt) | 2021-12-21 |
| TWI892985B (zh) | 2025-08-11 |
| CA3136969A1 (en) | 2020-10-29 |
| KR20210080339A (ko) | 2021-06-30 |
| JP2022530216A (ja) | 2022-06-28 |
| CL2021002757A1 (es) | 2022-06-10 |
| US20230053119A1 (en) | 2023-02-16 |
| UA128626C2 (uk) | 2024-09-04 |
| KR20200124176A (ko) | 2020-11-02 |
| EP3978518A1 (en) | 2022-04-06 |
| MY208040A (en) | 2025-04-10 |
| NZ782268A (en) | 2025-07-25 |
| EP3978518A4 (en) | 2022-11-02 |
| AU2020260931A1 (en) | 2021-12-09 |
| TW202100563A (zh) | 2021-01-01 |
| MX2021012964A (es) | 2021-12-10 |
| JOP20210282A1 (ar) | 2023-01-30 |
| TW202337914A (zh) | 2023-10-01 |
| PH12021552662A1 (en) | 2022-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220500A1 (es) | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 | |
| DOP2021000197A (es) | Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea | |
| AR105616A1 (es) | Proteínas de fusión | |
| HRP20110714T1 (hr) | Fuzijski proteini analoga glp-1 | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| CA2814780C (en) | Carrier immunoglobulins and uses thereof | |
| JP2018515088A5 (es) | ||
| MX2020009824A (es) | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. | |
| PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
| ATE546533T1 (de) | Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form | |
| PE20091931A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| CO6150201A2 (es) | Anticuerpo humanizado contra beta amiloide | |
| RU2015110250A (ru) | ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ | |
| ECSP064643A (es) | Proteinas de fusion de glp-1 | |
| AR072009A1 (es) | Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos | |
| CA2648109A1 (en) | Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| KR960704934A (ko) | 항혈전활성을 갖는 펩티드 및 이의 제조방법(Peptide having antithrombotic activity and process for producing the same) | |
| CR10591A (es) | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol | |
| JP2015504052A5 (es) | ||
| WO2021249012A9 (en) | Coronavirus vaccine compositions, methods, and uses thereof | |
| KR20180118550A (ko) | 이중 작용 단백질 및 그의 유도체의 제조방법 | |
| IL277838B1 (en) | Method for cleavage of solid phase-bound peptides from the solid phase |